One case of arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome featuring an incomplete and mild phenotype

Lianhu Yu†, Dan Li†, Ting Zhang, Yongmei Xiao, Yizhong Wang and Ting Ge*

Abstract
Background: Arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome is an autosomal recessive disorder caused by VPS33B or VIPAS39 mutations. VPS33B is a protein coding gene for vacuolar protein sorting 33 homologue B, which is expressed widely in tissues across the body and plays a critical role in maintaining cell polarity [1]. This syndrome involves multiple tissues, organs, or systems, such as muscle, liver, and kidney [2]. ARC syndrome is an uncommon disease that has a poor prognosis. Most of the reported patients presented some characteristic clinical features, including hypotonia with arthrogryposis, renal dysfunction, failure to thrive, neonatal cholestasis featuring low gamma-glutamyl transferase (GGT), and a high risk of haemorrhage caused by platelet dysfunction [2, 3]. Ichthyosis, cardiovascular disease, deafness, and other additional manifestations are also usually found among ARC syndrome patients. Studies have shown that more than 50% of patients experience

Background
Arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome is an autosomal recessive disorder caused by VPS33B or VIPAS39 mutations. VPS33B is a protein coding gene for vacuolar protein sorting 33 homologue B, which is expressed widely in tissues across the body and
dermatologic changes [4]. Few patients with ARC survive beyond one year; most patients die soon after the disease onset [5, 6]. There is a spectrum of phenotypes caused by VPS33B mutations. Patients with the c.1225 + 5G > C mutation in the VPS33B gene may have a mild phenotype and a longer lifespan [7]. Some patients do not present with all manifestations [6, 8], and there are some cases that include high GGT [9]. There is currently no cure for this disease, and further studies on ARC syndrome are urgently needed. Here, we report the case of a 13-year-old Chinese female with ARC syndrome with novel compound heterozygous mutations of VPS33B.

Case presentation
A 13-year-old girl was admitted to our hospital due to a history of intractable jaundice and skin itching for 1 month. The girl was the first child of a nonconsanguineous couple with unremarkable family history and was born healthy via normal delivery with a birth weight of 3200 g. No obvious or specific abnormalities were found in the girl during the perinatal period. Skin hyperkeratosis and mild limb bone abnormalities were identified during infancy and progressed to ichthyosis and obvious claw-like hands and feet at the age of 6 years. Furthermore, the patient presented with progressive itching and recurrent hand and foot desquamation since 6 years old.

One month before admission to our hospital, she was referred to a local hospital for medical support because of worsening jaundice and severe skin itching. The patient was diagnosed with acute liver failure, cholestasis, hypoalbuminemia, and abnormal blood coagulation in the local hospital and was managed with a series of treatments, including hepatoprotective treatment, plasma exchange, albumin infusion, and methylprednisolone pulse therapy. The patient’s liver function, hypoalbuminemia and blood coagulation function improved, while jaundice and skin itching were persistent. The patient was suspected to have a genetic disorder and was recommended for genetic testing. Then, she was discharged from the local hospital after drawing peripheral blood for whole-exome sequencing (WES). On admission, physical examination revealed normal growth with a height of 150 cm and a weight of 38 kg. Moderate skin yellowing, arthrogryposis (claw-shaped limbs), (Fig. 1 A, B), ichthyosis (Fig. 1C), and mild hepatomegaly were observed. The patient presented with mild gait abnormality and walked unsteadily on a broad base. Her muscle tone and strength were normal, and her neurological examination was normal. In addition, her hearing and vision screenings were normal. Laboratory tests showed normal routine blood testing results. Liver function tests revealed increased levels of alanine aminotransferase (ALT, 59 U/L, reference range: 5–40 U/L), direct bilirubin (DB, 117.3 μmol/L, reference range: 0–6.8 μmol/L), total bilirubin (TB, 231.92 μmol/L, reference range: 3.4–17.1 μmol/L), and total bile acid (TBA, 210.5 μmol/L, reference range: 0–10 μmol/L), while aspartate aminotransferases (AST) and gamma-glutamyltransferase (GGT) were normal. Multiple urinalysis showed positive urine bilirubin and urobilinogen but without proteinuria and amino aciduria. Her blood coagulation functions were normal. Alpha fetal protein (AFP) was normal, autoantibody analyses were normal, and liver damaging pathogens Epstein Barr virus (EBV), TORCH, hepatitis A, B, C, and E were all normal. Liver biopsy revealed the absence of the bile duct, and the gross bile ducts were severely dilated and filled with fine particles of bile (Fig. 2). Electron microscopy showed hepatocytes of unequal size and disorganized arrangement with dilated hepatic sinuses (Fig. 3). The mitochondria were swollen, the rough endoplasmic reticulum was hyperplastic and vesicular, the lysosomes were increased, and no viral particles were seen (Fig. 3). A previous head
MRI from a local hospital was normal. In addition, WGS results revealed novel compound heterozygous mutations of VPS33B, c.1081 C > T (p.Q361X,257)/c.244 T > C (p. C82R), which was inherited from her father and mother as the parents are heterozygote carriers. Neither variant has been reported previously. In silico analysis predicted that the variant c.1081 C > T (p. Q361X, 257) is pathogenic through abolishment of protein translation, and c.244 T > C (p. C82R) is likely pathogenic according to MutationTaster [10]. Finally, the patient was diagnosed with ARC syndrome based on the clinical manifestations and genetic testing results.

During hospitalization, the patient was treated with ursodeoxycholic acid (250 mg, TID) for cholestasis, methylprednisolone sodium succinate (10 mg, QD) for inflammation, and cholestyramine (4 g, QD) for pruritus. External applications of triamcinolone acetonide econazole cream and urea ointment were used to relieve ichthyosis. Fortunately, the patient’s cholestasis and liver function improved after 1 week of treatment. Her symptoms of jaundice and skin itching were relieved significantly; however, the dermal and arthrosis manifestations persisted. The patient was discharged after 10 days of hospitalization and was managed with maintenance treatment of ursodeoxycholic acid (250 mg, TID). To date, cholestatic jaundice has been well controlled, and her daily quality of life has improved (Table 1).

**Discussion and conclusions**

Generally, most ARC cases are often diagnosed in infancy, as the onset of this disease is usually shortly after birth, and it has a rapid progression. The major causes of death include recurrent infection, dehydration or bleeding [11]. Our patient presented only 3 typical symptoms of cholestasis, arthrogryposis, and ichthyosis. Compared to typical ARC syndrome patients, the patient’s renal function is normal based on urine test results. No renal tubular dysfunction, such as renal tubular acidosis, nephrogenic diabetes insipidus, or glucosuria, appeared. She went for clinical advice because of jaundice and itchy skin, but when we examined her medical history,

| Biochemical indices | Reference | 20.09.10 | 20.9.16 | 20.10.22 | 21.7.28 | 21.7.31 |
|--------------------|-----------|----------|----------|----------|----------|----------|
| TB (μmol/L)        | 3.4–17.1  | 231.92   | 156.72   | 32.74    | 16.18    | 10.45    |
| DB (μmol/L)        | 0–6.8     | 117.3    | 77.5     | 12.00    | 2.40     | 1.80     |
| ALT (U/L)          | 5–40      | 59       | 90       | 76       | 24       | 20       |
| AST (U/L)          | 8–40      | 39       | 66       | 71       | 31       | 27       |
| GGT (U/L)          | 7–32      | 23       | 21       | 15       | 18       | 17       |

**Table 1** Main results of patient’s liver function during follow-up

TB Total serum bilirubin, DB Direct bilirubin, ALT Alanine aminotransferase, AST Aspartate aminotransferase, GGT Gamma-glutamyltransferase
she showed a characteristic presentation of this disease at an early age. After birth, her skin gradually showed an appearance similar to fish scales with thickened stratum corneum, and her limbs gradually became deformed like claws. At the age of 6 years old, the patient's dermal manifestations became more similar to the characteristic appearance of ichthyosis with skin itching, which worsened with her growth. Together with her clinical symptoms, signs and genetic finding of pathogenic VPS33B mutations, the patient was diagnosed with ARC syndrome at the age of 13 years old. The delayed diagnosis of our case may be due to early ARC symptoms (ichthyosis and arthrogryposis) not being recognized as part of the ARC syndrome, possibly due to a lack of jaundice, and it may be that many physicians overlooked the diagnosis due to its rarity and lack of expertise. Although most of the reported ARC patients died in their early ages (<12 months), patients with incomplete and mild phenotypes are likely to achieve a prolonged lifespan. In addition to the patient presented in this study, several patients with extended lifetimes who had similar conditions of mild symptoms and slow progression were reported [8]. Five reported ARC syndrome patients with attenuated or incomplete phenotypes are summarized in Table 2. All these patients had a relatively long lifespan, although their growth failure and quality of life could not be improved significantly [6, 12, 13]. The prolonged lifespan of ARC patients may be attributed to mild symptoms and could be managed by symptomatic treatments. Currently, our patient is 14 years old, and her cholestasis was alleviated by maintenance treatment with ursodeoxycholic acid. Her daily quality of life is improved, and she is expected to have a longer life despite the persistent dermal manifestations and arthrosis symptoms.

The mechanisms of ARC syndrome are not completely understood, but it is believed to be associated with abnormal expression of VPS33B protein caused by VPS33B mutations. The VPS33B protein is a Sec1/Munc18 family protein involved in membrane trafficking through interacting with the Rab11 family at recycling

| Reference | Age | Mutation | Typical Phenotype | Other manifestations | Examinations | Treatments | Prognosis |
|-----------|-----|----------|-------------------|----------------------|--------------|------------|-----------|
| [13]      | 2.5y| c.240–577_290-156del c.1225 + 5G > C | 1. Ichthyosis 2. Pruritus 3. Growth failure 4. Hearing loss | MRI: dysmorphic ventricle | 1. Conventional treatments 2. Cutaneous biliary diversion 3. Supplemental feeds via gastric tube | 1. Cholestasis and ichthyosis showed no response to conventional therapy 2. Ichthyosis improved after cutaneous biliary diversion 3. Growth improved with supplemental feeds via gastric tube | 1. Language skill improved with hearing aid 2. Growth failure and pruritus wasn’t improved |
| [13]      | 12 m| c.1261_1262delCA c.1225 + 5G > C | 1. Pruritus 2. Growth failure 3. Hearing loss 4. Hypercholanemia 5. Abnormal dental composition | MRI: hin corpus callosum and diffuse paucity of white matter | 1. Rifampicin, phenobarbitone, and ursodeoxycholic acid treatment 2. Hearing aid 3. Dysplasia corrective surgery | 1. Cholestasis and ichthyosis improved after conventional treatment 2. Cholestasis showed no response to conventional therapy 3. Ichthyosis improved after cutaneous biliary diversion 4. Growth failure | 1. Cholestasis and ichthyosis showed no response to conventional treatment 2. Ichthyosis improved after cutaneous biliary diversion 3. Growth improved with supplemental feeds via gastric tube | 1. Language skill improved with hearing aid 2. Growth failure and pruritus wasn’t improved |
| [7]       | 7.7y| c.1157A > C (p.His386Pro) | 1. Growth failure 2. Dry skin | MRI: marked hypoplasia of corpus callosum, decrease in white matter volume, increased T1 signal in basal ganglia | Biliary diversion | Pruritus improved |
| [7]       | 3y  | c.1157A > C (p.His386Pro) | 1. Growth failure 2. Ichthyosis | MRI: thin and underdeveloped corpus callosum, white matter hypoplasia and delayed myelination, increased signal in basal ganglia | Biliary diversion | Pruritus improved |
| [7]       | 11y | 1225 + 5G > C and partial deletion in the VPS33B gene | 1. Ichthyosis 2. Hearing loss 3. Growth failure | Ultrasound: small kidneys; echogenic liver without hepatosplenomegaly | Potassium citrate and enalapril | N/A |
endosomes that plays a key role in establishing structural and functional aspects of hepatocyte polarity [14]. The deficiency of VPS33B protein leads to mislocalization of canalicular proteins, such as ATP binding cassette subfamily B member 11 (ABCB11), in hepatocytes that influence biliary physiology [14, 15]. In healthy individuals, bile acid is secreted via ABCB11 in hepatocytes. VPS33B protein combines with apical-basolateral polarity regulator (VIPAR), which forms a complex that helps the trafficking of ABCB11 towards the canalicular side of hepatocytes by interacting with apical recycling endosomes (AREs). Mutations in VPS33B lead to a malfunction of VPS33B/VIPAR complex, which cannot bind with ARE, causing ABCB11 to move to the basolateral side and leading to cholestasis in ARC patients [14, 15]. Furthermore, hepatic VPS33B deficiency was demonstrated to aggravate cholic acid-induced cholestatic liver injury in mice [16]. Ichthyosis presented in ARC patients is also a result of insufficiency of VPS33B, as the lack of VPS33B protein can lead to unusual epidermal lamellar bodies and abnormal stratum corneum formation construction [17]. VPS33B knockout mice showed a similar skin appearance to ARC syndrome patients [18]. In addition to ARC, VPS33B mutations can cause another similar disease, autosomal recessive keratoderma-ichthyosis-deafness syndrome (ARKID) [19]. The typical manifestations of ARKID include ichthyosis, hearing loss, severe failure to thrive and osteopenia [19, 20]. Normally, doctors can differentiate ARKID and ARC in patients with VPS33B mutations according to the typical symptoms. Nevertheless, further research is needed to investigate the correlations between VPS33B mutations and clinical manifestations in both ARKID and ARC patients.

Currently, there is no cure for ARC syndrome. Symptomatic therapies are mostly used to manage patients with ARC syndrome. Fortunately, the major manifestation of our patient, i.e., cholestasis, was significantly relieved by ursodeoxycholic acid during hospitalization and is well-controlled by maintenance treatment of ursodeoxycholic acid. In most cases, conventional treatments are always useless, while biliary diversion can relieve pruritus in some mild cases [6, 12, 13]. In addition, some methods, such as low-density lipoprotein apheresis and biliary diversion, have been reported to improve symptoms, especially pruritus, but the efficacy for improving prognosis was not satisfactory [21]. A report showed that liver transplantation may provide a promising way to cure cholestasis in patients [22]. Thus, genetic counselling before pregnancy and prenatal genetic testing are important for families with a history of ARC syndrome due to its poor prognosis [23].

In summary, our presented case features a prolonged survival time of ARC syndrome. Together with other reported cases with prolonged lifespan, the prognosis of ARC patients likely depends on the gene mutation type, phenotype and time of disease onset with unrevealed mechanisms. Thus, early diagnosis and suitable supporting treatments are important in improving the quality of life of patients with ARC syndrome.

**Abbreviations**

ARC syndrome: Arthrogryposis-renal dysfunction-cholestasis syndrome; ALT: Alanine aminotransferase; AST: Aspartate aminotransferases; TBA: Total bile acid; GGT: Gamma-glutamyltransferase; WES: Whole-exome sequencing; DB: Direct bilirubin; TB: Total bilirubin; ARKID: Keratoderma-ichthyosis-deafness syndrome.

**Acknowledgements**
The authors appreciate the support and participation of the family in this study.

**Authors’ contributions**

TZ and YW contributed to the study conception and design. DL, YX and TG acquired the clinical data, LY and TG drafted the manuscript, and YW edited and revised the manuscript. All authors read and approved the final manuscript.

**Funding**

This work was supported by grants from the National Natural Science Foundation of China (grant numbers 81870373 and 81900472). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Availability of data and materials**

The original contributions presented in the study are included in the article or supplementary materials; further inquiries can be directed to the corresponding author.

**Declarations**

**Ethics approval and consent to participate**

Written consent was obtained from the parents of the patients for the study and the publication of this case report. All personal information of both patients was excluded from this report. The study was approved by the Regional Ethical Review Board of Shanghai Children’s Hospital.

**Consent for publication**

Written informed consent for publication of identifying images or other personal or clinical details was obtained from the patient’s parents.

**Competing interests**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Received:** 8 January 2022  **Accepted:** 15 June 2022  **Published online:** 27 June 2022

**References**

1. Lee MJ, Suh CR, Shin JH, Lee JH, Lee Y, Eun BL, et al. A novel VPS33B variant identified by exome sequencing in a patient with arthrogryposis-renal dysfunction-cholestasis syndrome. Pediatr Gastroenterol Hepatol Nutr. 2019;22(6):581-1.
2. Taha D, Khider A, Cullinan AR, Gissen P. A novel VPS33B mutation in an ARC syndrome patient presenting with osteopenia and fractures at birth. Am J Med Genet A. 2007;143a(23):2835–7.

3. Agaeu A, Sheppard S, Lin HC. A Novel VPS33B mutation causing a mild phenotype of arthrogryposis, renal dysfunction, and cholestasis syndrome. J Pediatr Gastroenterol Nutr. 2019;69(2):e55–6.

4. Zhou Y, Zhang J. Arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome: from molecular genetics to clinical features. Ital J Pediatr. 2014;40:77.

5. Gissen P, Tee L, Johnson CA, Genin E, Caliebe A, Chitayat D, et al. Clinical and molecular genetic features of ARC syndrome. Hum Genet. 2006;120(3):396–409.

6. Del Brío CR, Squires JE, McKiernan PJ. A novel mutation in VPS33B gene causing a milder ARC syndrome phenotype with prolonged survival. JIMD Rep. 2019;47(1):4–8.

7. Duong MD, Rose CM, Reidy KJ, Del Rio M. An uncommon case of arthrogryposis, renal dysfunction, and cholestasis (ARC) syndrome and review of the renal involvement: answers. Pediatr Nephrol. 2020;35(2):249–51.

8. Qiu YL, Liu T, Abuduxikuer K, Hao CZ, Gong JY, Zhang MH, et al. Novel missense mutation in VPS33B is associated with isolated low gamma-glutamyltransferase cholestasis: Attenuated, incomplete phenotype of arthrogryposis, renal dysfunction, and cholestasis syndrome. Hum Mutat. 2019;40(12):2247–57.

9. Wang JS, Zhao J, Li LT. ARC syndrome with high GGT cholestasis caused by VPS33B mutations. World J Gastroenterol. 2014;20(16):4830–4.

10. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014;11(4):361–2.

11. Agakidou E, Agakidis C, Kambouris M, Printza N, Farini M, Vourda E, et al. A novel mutation of VPS33B gene associated with incomplete arthrogryposis-renal dysfunction-cholestasis phenotype: Case Rep Genet. 2020;2020:8872294.

12. Bull LN, Mahmoodi V, Baker AJ, Jones R, Strautnieks SS, Thompson RJ, et al. VPS33B mutation with ichthyosis, cholestasis, and renal dysfunction but without arthrogryposis: incomplete ARC syndrome phenotype. J Pediatr. 2006;148(2):269–71.

13. Smith H, Galmes R, Gogolina E, Straatman-Iwanowska A, Reay K, Banushi B, et al. Associations among genotype, clinical phenotype, and intracellular localization of trafficking proteins in ARC syndrome. Hum Mutat. 2012;33(2):1656–64.

14. Hanley J, Dhar DK, Mazzacuva F, Fiadeiro R, Burden JJ, Lyne AM, et al. Vps33b is crucial for structural and functional hepatocyte polarity. J Hepatol. 2017;66(S1):1001–11.

15. Li Q, Sun Y, van Uzenden O, SCD. A link between intrahepatic cholestasis and genetic variations in intracellular trafficking regulators. Biology (Basel). 2021;10(2):119.

16. Fu KI, Chen P, Zhou YY, Jiang YM, Gao Y, Zhang HZ, et al. Hepatic Vps33b deficiency aggravates cholic acid-induced cholestatic liver injury in male mice. Acta Pharmacol Sin. 2022;43(4):933–40.

17. Hershkovitz D, Mandel H, Ishida-Yamamoto A, Chefetz I, Hino B, Luder A, et al. Defective lamellar granule secretion in arthrogryposis, renal dysfunction, and cholestasis syndrome caused by a mutation in VPS33B. Arch Dermatol. 2008;144(3):334–40.

18. Rogerson C, Gissen P. VPS33B and VIPAR are essential for epidermal lamellar body biogenesis and function. Biochim Biophys Acta Mol Basis Dis. 2018;1864(5 Pt A):1606–21.

19. Gruber R, Rogerson C, Windpassinger C, Banushi B, Straatman-Iwanowska A, Hanley J, et al. Autosomal Recessive Keratoderma-Ichthyosis-Deafness (ARKID) syndrome is caused by VPS33B mutations affecting rab protein interaction and collagen modification. J Invest Dermatol. 2017;137(4):845–54.

20. Alter S, Hotz A, Jahn A, Di Donato N, Schröck E, Smitka M, et al. Novel VPS33B mutation in a patient with autosomal recessive keratoderma-ichthyosis-deafness syndrome. Am J Med Genet A. 2018;176(1):2862–6.

21. Rosales A, Mhlabik M, Gissen P, Segarra O, Redecillas S, Arieta C. Severe renal fanncone and management strategies in arthrogryposis-renal dysfunction-cholestasis syndrome: a case report. BMC Nephrol. 2018;19(1):44.

22. Dehghani SM, Bahador A, Nikeghbalian S, Salah H, Geramizadeh B, Malekpour A, et al. Liver transplant in a case of arthrogryposis-renal tubular dysfunction-cholestasis syndrome with severe intractable pruritus. Exp Clin Transplant. 2013;11(3):290–2.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.